Jack Y. Zhang - 06 Mar 2023 Form 4 Insider Report for Amphastar Pharmaceuticals, Inc. (AMPH)

Role
CEO & Chief Scientific Officer, Director, 10%+ Owner
Signature
/s/ Eva Wen, by power of attorney for Jack Y. Zhang
Issuer symbol
AMPH
Transactions as of
06 Mar 2023
Transactions value $
$0
Form type
4
Filing time
08 Mar 2023, 15:05:27 UTC
Previous filing
23 May 2022
Next filing
17 Mar 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AMPH Common Stock Award $0 +81.4K +3.87% $0.00 2.19M 06 Mar 2023 Direct F1
transaction AMPH Common Stock Award $0 +34.3K +2.29% $0.00 1.53M 06 Mar 2023 See footnote F1, F2
holding AMPH Common Stock 6.83M 06 Mar 2023 See footnote F3
holding AMPH Common Stock 5K 06 Mar 2023 See footnote F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AMPH Employee Stock Option (right to buy) Award $0 +171K $0.00 171K 06 Mar 2023 Common Stock 171K $35.13 Direct F5
transaction AMPH Employee Stock Option (right to buy) Award $0 +72.3K $0.00 72.3K 06 Mar 2023 Common Stock 72.3K $35.13 See footnote F2, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported shares are represented by restricted stock units, or RSUs, which vest in four equal annual installments beginning on March 6, 2024.
F2 The securities are held of record by Mary Z. Luo. The reporting persons are husband and wife.
F3 The shares are held of record by Applied Physics & Chemistry Laboratories, Inc., of which the reporting persons and The Bill Luobei Zhang 2004 Irrevocable Trust are the sole owners.
F4 The shares are held of record in an account for the benefit of the reporting persons' son. The reporting persons disclaim beneficial ownership of these shares, and the inclusion of these shares in this report should not be deemed an admission of beneficial ownership of any such shares for purposes of Section 16, or for any other purpose.
F5 The shares subject to the option vest in four equal annual installments beginning on March 6, 2024.